INTERVENTIONALEnded2024-517751-13-01
Cannabidiol for reducing drinking in alcohol use disorder and modifying the effects of alcohol on the brain and the liver: a phase 2 clinical trial.- The CARAMEL Study
The primary objective of the CARAMEL study is to compare the reduction in alcohol drinking between CBD and placebo (PCB), in a population of patients with AUD and heavy drinking level at baseline (i.e., 12 standard drinks (sd)/day or more). The drinking reduction level will be defined by the total consumption in the 28 days prior to inclusion, minus the total consumption of the 28 last days of the study (weeks 8 to 12).
Locally preserved from EU Clinical Trials Information SystemOpen EU Clinical Trials Information System↗last source update 2026-04-23
What this record can show
Protocol only - no registry results posted
This locally preserved record separates the registered protocol from source-reported registry results. Neither is a treatment recommendation.
Registry facts
Study at a glance
- Phase
- PHASEII
- Enrollment
- 76 (ACTUAL OR ANTICIPATED)
- Start date
- 2024-12-26
- Sponsor
- Centre Hospitalier Le Vinatier
- Design
- Not reported
- Locations
- 0
- Results record
- Not present in registry snapshot
It is a phase II clinical trial
Psychiatric disordersPsychiatric disorders
Linked local records
Related local records
Local links use governed condition terms or exact source-reported intervention names. They are navigation candidates, not efficacy claims.
Cannabinoids and active compounds
No governed compound link was found.
Medicines
No exact medicine-name link was found.
Interventions
What was registered
No structured intervention was reported.
Eligibility
Population and criteria
- Sex
- Not reported
- Minimum age
- Not reported
- Maximum age
- Not reported
- Healthy volunteers
- Not reported
Eligibility criteria
- ['Being aged 18 years, or more', 'Comprendre le français', 'Having read the information procedure and signed the informed consent sheet', 'Being affiliated with health insurance', 'DSM-5 criteria for AUD (all stages) (American Psychiatric Association, 2013)', 'Average drinking level of at least 12 standard-drinks (120g of ethanol) per day over the month prior to inclusion (i.e., a total alcohol consumption of 336 standard-drinks during the 28-day assessment period prior to inclusion), using the A-TLFB'] ['At least one day of abstinence (no alcohol drinking) during the month prior to inclusion', 'Pregnancy, lactation, or insufficient contraceptive measure (precautionary measure) (See 5.2 for acceptable birth control methods)', 'Patients with cancer, HIV, pulmonary arterial hypertension, epilepsy and with rifampicin, St. John’s wort, everolimus, tacrolimus or triazole antifungal agents like posaconazole, fluconazole.', 'History of vascular accident and/or cardiac arrhythmias and/or myocardial infarction', 'Patients receiving acamprosate, naltrexone, disulfiram, nalmefene, topiramate, baclofen for AUD within 30 days prior to screening.', 'MRI contraindication: pacemaker, insulin pump, heart metal valve, cochlear implant…', 'Known hypersensitivity to the active principle (cannabidiol) or excipients', 'Person under tutorship or curatorship', 'Criteria for liver cirrhosis (Child-Pugh B or C)', 'DSM-5 criteria for schizophrenia, schizoaffective disorder, or bipolar disorder, using the MINI 7.0.2', 'Current suicidality, using the MNI 7.0.2', 'Lifelong history of suicide attempts', 'Lifelong history or current DSM-5 criteria for substance use disorder (other than alcohol or nicotine) using the MINI 7.0.2', 'Any detected use of cannabis or any other cannabinoid within 60 days prior to screen', 'Patients with transaminase elevations greater than 3 times upper the limit of normal and bilirubin greater than 2 times upper the limit of normal', "Impaired medical condition (investigator's decision)"]
Publications
Locally readable linked articles
0No exact PMID-linked public article is currently readable locally.
Snapshot provenance
- Snapshot
- d71e2c4b-4f67-4dc2-af6b-e5b57bebc77e
- Retrieved
- 25/08/2026, 17:12:51
- SHA-256
- 6f2b332a74a02a578cd82701a6d2559a7539ea6e633a6a85584957c5e37cf433